EP4377292A4 - Water-soluble prodrugs, conjugates and their uses - Google Patents
Water-soluble prodrugs, conjugates and their usesInfo
- Publication number
- EP4377292A4 EP4377292A4 EP22848817.7A EP22848817A EP4377292A4 EP 4377292 A4 EP4377292 A4 EP 4377292A4 EP 22848817 A EP22848817 A EP 22848817A EP 4377292 A4 EP4377292 A4 EP 4377292A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- conjugates
- water
- soluble prodrugs
- prodrugs
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL28520821 | 2021-07-28 | ||
| PCT/IL2022/050782 WO2023007481A1 (en) | 2021-07-28 | 2022-07-20 | Water soluble prodrug, conjugates and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4377292A1 EP4377292A1 (en) | 2024-06-05 |
| EP4377292A4 true EP4377292A4 (en) | 2026-06-03 |
Family
ID=85086377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22848817.7A Pending EP4377292A4 (en) | 2021-07-28 | 2022-07-20 | Water-soluble prodrugs, conjugates and their uses |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4377292A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024532677A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117999254A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022318483A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3226393A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL310354A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023007481A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566631A1 (en) * | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020188061A1 (en) * | 2019-03-19 | 2020-09-24 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017531620A (ja) * | 2014-09-12 | 2017-10-26 | ジェネンテック, インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| KR102710962B1 (ko) * | 2017-07-04 | 2024-09-27 | 주식회사 인투셀 | 절단성 링커를 포함하는 화합물 및 이들의 용도 |
| AU2019365238A1 (en) * | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
-
2022
- 2022-07-20 AU AU2022318483A patent/AU2022318483A1/en active Pending
- 2022-07-20 CN CN202280053086.7A patent/CN117999254A/zh active Pending
- 2022-07-20 IL IL310354A patent/IL310354A/en unknown
- 2022-07-20 WO PCT/IL2022/050782 patent/WO2023007481A1/en not_active Ceased
- 2022-07-20 EP EP22848817.7A patent/EP4377292A4/en active Pending
- 2022-07-20 CA CA3226393A patent/CA3226393A1/en active Pending
- 2022-07-20 JP JP2024505333A patent/JP2024532677A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020188061A1 (en) * | 2019-03-19 | 2020-09-24 | Paul Scherrer Institut | Transglutaminase conjugation method with a glycine based linker |
Non-Patent Citations (5)
| Title |
|---|
| CONILH LOUISE ET AL: "Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform", PHARMACEUTICALS, vol. 14, no. 3, 9 March 2021 (2021-03-09), pages 247, XP055953984, ISSN: 1424-8247, DOI: 10.3390/ph14030247 * |
| KUMAR RAJESH ET AL: "Hypoxia-directed and activated theranostic agent: Imaging and treatment of solid tumor", BIOMATERIALS ELSEVIER, AMSTERDAM, NL, vol. 104, 14 July 2016 (2016-07-14), pages 119 - 128, XP029681211, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2016.07.010 * |
| See also references of WO2023007481A1 * |
| VINEBERG JACOB G. ET AL: "Design, Synthesis, and Biological Evaluations of Tumor-Targeting Dual-Warhead Conjugates for a Taxoid-Camptothecin Combination Chemotherapy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 13, 5 June 2014 (2014-06-05), pages 5777 - 5791, XP055954712, ISSN: 0022-2623, DOI: 10.1021/jm500631u * |
| YAMAZAKI CHISATO M. ET AL: "Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance", NATURE COMMUNICATIONS, vol. 12, no. 1, 10 June 2021 (2021-06-10), XP055940303, DOI: 10.1038/s41467-021-23793-7 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022318483A1 (en) | 2024-02-22 |
| EP4377292A1 (en) | 2024-06-05 |
| CN117999254A (zh) | 2024-05-07 |
| WO2023007481A1 (en) | 2023-02-02 |
| IL310354A (en) | 2024-03-01 |
| JP2024532677A (ja) | 2024-09-10 |
| CA3226393A1 (en) | 2023-02-02 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240227 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C07C0211460000 Ipc: A61K0047680000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20260506 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/68 20170101AFI20260429BHEP Ipc: A61P 35/00 20060101ALI20260429BHEP Ipc: C07D 491/22 20060101ALI20260429BHEP Ipc: C07K 16/32 20060101ALI20260429BHEP Ipc: C07C 69/00 20060101ALI20260429BHEP Ipc: C07C 211/46 20060101ALI20260429BHEP Ipc: C07K 16/00 20060101ALI20260429BHEP |